Abstract library

10 results for "Hayes".
#2883 Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study
Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.
Conference: 17th Annual ENETS Conference (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Alberto Carmona-Bayonas
#1787 Towards Personalizing PRRT with [177Lu]-Dotatate to Minimise Renal Toxicity in Neuroendocrine Tumour Patients
Introduction: The kidney is a dose-limiting organ in [177Lu]-Dotatate PRRT (Lutate) and thus renal function is an important prescribing consideration for NET patients. The effect of baseline renal function on kidney absorbed dose is unclear.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Enid Eslick
#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).
Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso
#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)
Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Aimee Hayes
#2027 Predictors of Antiproliferative Effect of Lanreotide Autogel (LA) as First-Line Therapy for Advanced Neuroendocrine Tumors (NETs)
Introduction: The antiproliferative properties of LA in GEP NETs were demonstrated in the recently published CLARINET study
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Faidon Laskaratos
#2246 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Characterisation of Prevalence and Prognosis in the Pulmonary Carcinoid Population
Introduction: DIPNECH is considered a rare condition and the natural history is poorly described. It is thought to give rise to pulmonary carcinoids (PCs) (>5mm) or tumourlets (≤5mm).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Aimee Hayes
Authors: Hayes A, Banks J, Shah H, Luong T V, ...
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni
#3038 Managing Neuroendocrine Neoplasms (NEN) in Association with HIV Infection: A Single Institution Experience
Introduction: There is a paucity of knowledge regarding NEN and HIV infection in the literature.
Conference: 17th Annual ENETS Conference (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Aimee R Hayes
Authors: Hayes A R, Smith K, Liu M, Jenkinson S, ...
#1463 Graph-Theoretic Definition of Neuroendocrine Disease – A Tumor Specific Mathematical Toolbox for Assessing Neoplastic Behaviour
Introduction: Widespread availability of high throughput screens has led to the rapid adaptation of mathematics in biomedicine.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Authors: Drozdov I, Kidd M, Modlin I, ...
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team